Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Net Income (2016 - 2025)

Rein Therapeutics filings provide 10 years of Net Income readings, the most recent being $7.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 16.6% year-over-year to $7.4 million, compared with a TTM value of -$10.6 million through Dec 2025, up 21.33%, and an annual FY2025 reading of -$9.9 million, up 26.61% over the prior year.
  • Net Income hit $7.4 million in Q4 2025 for Rein Therapeutics, up from -$5.5 million in the prior quarter.
  • The five-year high for Net Income was $8.8 million in Q4 2024, with the low at -$9.0 million in Q2 2024.
  • Median Net Income over the past 5 years was -$6.2 million (2022), compared with a mean of -$4.7 million.
  • The largest YoY upside for Net Income was 220.99% in 2024 against a maximum downside of 380.8% in 2024.
  • Year by year, Net Income stood at -$6.8 million in 2021, then soared by 31.0% to -$4.7 million in 2022, then crashed by 55.01% to -$7.3 million in 2023, then skyrocketed by 220.99% to $8.8 million in 2024, then dropped by 16.6% to $7.4 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at $7.4 million, -$5.5 million, and -$6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.